Pelthos Therapeutics Files 8-K for Reg FD Disclosure

TL;DR

Pelthos Therapeutics (PLTH) filed an 8-K on Sep 3 for events on Sep 2. Standard disclosure filing.

AI Summary

Pelthos Therapeutics Inc. filed an 8-K on September 3, 2025, reporting an event on September 2, 2025. The filing is primarily for Regulation FD Disclosure and includes Financial Statements and Exhibits. The company, formerly known as Channel Therapeutics Corp and Chromocell Therapeutics Corp, is incorporated in Nevada and headquartered in Durham, NC.

Why It Matters

This 8-K filing indicates important disclosures or events have occurred that are relevant to investors, requiring immediate reporting to the SEC.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for disclosure and exhibits, not indicating any immediate financial distress or significant operational change.

Key Players & Entities

• Pelthos Therapeutics Inc. (company) — Registrant
• Channel Therapeutics Corp (company) — Former Company Name
• Chromocell Therapeutics Corp (company) — Former Company Name
• September 2, 2025 (date) — Earliest event reported
• September 3, 2025 (date) — Filing Date
• Durham, NC (location) — Principal Executive Office

FAQ

From the Filing

0001753926-25-001425.txt : 20250903 0001753926-25-001425.hdr.sgml : 20250903 20250903083118 ACCESSION NUMBER: 0001753926-25-001425 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 36 CONFORMED PERIOD OF REPORT: 20250902 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250903 DATE AS OF CHANGE: 20250903 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pelthos Therapeutics Inc. CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 863335449 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 251287822 BUSINESS ADDRESS: STREET 1: 4020 STIRRUP CREEK DRIVE STREET 2: SUITE 110 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-908-2422 MAIL ADDRESS: STREET 1: 4020 STIRRUP CREEK DRIVE STREET 2: SUITE 110 CITY: DURHAM STATE: NC ZIP: 27703 FORMER COMPANY: FORMER CONFORMED NAME: Channel Therapeutics Corp DATE OF NAME CHANGE: 20241118 FORMER COMPANY: FORMER CONFORMED NAME: Chromocell Therapeutics Corp DATE OF NAME CHANGE: 20220323 8-K 1 g084940_8-k.htm 8-K false 0001919246 0001919246 2025-09-02 2025-09-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): September 2, 2025   Pelthos Therapeutics Inc.   (Exact name of registrant as specified in its charter)   Nevada   001-41964   86-3335449 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   4020 Stirrup Creek Drive , Suite 110 Durham , NC   27703 (Address of registrant’s principal executive office)   (Zip code)   Registrant’s telephone number, including area code: (919) 908-2400   (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   PTHS   The NYSE American LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 7.01. Regulation FD Disclosure.   On September 2, 2025, Pelthos Therapeutics Inc. (the “Company”) issued a press release announcing that its Chief Executive Officer, Scott Plesha, and Chief Financial Officer, Francis Knuettel II, will present at the Wells Fargo 2025 Healthcare Conference in Boston, Massachusetts. Ma